The New Frontier in Menopausal Care: Inside AVA-291, the First “Non-Aromatizing” Testosterone for Women
For decades, the conversation surrounding Menopause Hormone Therapy (MHT) has been dominated by two hormones: estrogen and progesterone. Yet, biologically, healthy women produce significant amounts of another vital messenger: testosterone. Throughout reproductive life, women produce more testosterone than estradiol by mass. When ovaries wind down during perimenopause and menopause, androgen production drops substantially.
Despite millions of women experiencing profound fatigue, cognitive fog, loss of muscle tone, and a complete collapse in libido (Hypoactive Sexual Desire Disorder, or HSDD), there is currently no FDA-approved testosterone product formulated specifically for women in the United States. At The Natural Path, we have been providing low dose testosterone therapy for women safely and effectively but “off-label.” We look forward to an FDA approved product.
Women seeking treatment have had to rely on compounding pharmacies or fractionated doses of male-centric topical gels—both fraught with inconsistent dosing, skin transfer risks, and regulatory ambiguity.
Enter AVA-291 (d3-testosterone), a therapeutic candidate under development by biotechnology company Aviva Bio. Designed specifically around the nuances of female endocrinology, AVA-291 aims to deliver the therapeutic benefits of testosterone while engineering away its most persistent safety dilemma: the risk of driving breast cell proliferation.
Here is a deep dive into how this drug works, its clinical development progress, potential benefits, and when it might become available.
1. The Science: Why AVA-291 Is a Molecular Breakthrough
To understand why AVA-291 has generated attention across reproductive endocrinology, it helps to understand why ordinary testosterone was sidelined in female medicine for so long.
The Aromatization Problem
When standard testosterone enters human tissue, it operates along two metabolic pathways:
-
It binds directly to the androgen receptor (or converts via 5-alpha reductase to DHT) to mediate androgenic effects—fueling energy, muscle mass, bone mineralization, and libido.
-
It interacts with an enzyme called aromatase, which chemically converts (aromatizes) testosterone directly into estradiol (E2).
In women, local breast tissue expresses aromatase. Historically, clinical development of female testosterone faced significant headwinds over concerns that extra-systemic testosterone would convert locally into estrogens in breast tissue, potentially stimulating the growth of Estrogen Receptor-Positive (ER+) breast tumors. In fact, standard oncology treatment for ER+ breast cancer often relies on aromatase inhibitors to prevent this very conversion.
The Deuterium “Kinetic Isotope” Fix
AVA-291 is known chemically as d3-testosterone (d3-T). It is an isotopologue of testosterone, meaning its three-dimensional structure and receptor binding profile are practically indistinguishable from natural testosterone—with one critical modification: three specific hydrogen atoms have been replaced with deuterium (a stable, non-radioactive isotope of hydrogen).
Because the carbon-deuterium bond is significantly stronger than a carbon-hydrogen bond (a chemical principle known as the Kinetic Isotope Effect), the aromatase enzyme cannot easily cleave and convert the molecule into estradiol.
-
Retained Power: It binds to and translocates the androgen receptor identically to ordinary testosterone.
-
Selective Resistance: It resists conversion into estrogen.
In preclinical data presented at the American Association for Cancer Research (AACR), AVA-291 showed approximately 1,000-fold lower potential to stimulate breast cancer cell proliferation than natural testosterone in ER+ breast cancer cell models.
2. Potential Benefits: What Can AVA-291 Do for Menopausal Women?
Because AVA-291 cleanly targets the androgen receptor without triggering collateral estrogenic pathways, it could have a broad therapeutic footprint in postmenopausal women across multiple physical and psychological domains.
┌────────────────────────────────────────────────────────┐
│ CORE THERAPEUTIC SPECTRUM OF AVA-291 │
├─────────────────────────┬──────────────────────────────┤
│ Sexual Health │ • Restoration of libido │
│ │ • Receptive sexual desire │
│ │ • Clitoral / genital blood │
│ │ flow & responsiveness │
├─────────────────────────┼──────────────────────────────┤
│ Cognitive & Mood │ • Alleviation of brain fog │
│ │ • Motivation & drive │
│ │ • Mood stability & stamina │
├─────────────────────────┼──────────────────────────────┤
│ Musculoskeletal │ • Lean muscle synthesis │
│ │ • Prevention of sarcopenia │
│ │ • Bone mineral density (BMD) │
│ │ • Joint resilience │
└─────────────────────────┴──────────────────────────────┘
A. Hypoactive Sexual Desire Disorder (HSDD)
The FDA has explicitly advised Aviva Bio to pursue Hypoactive Sexual Desire Disorder (HSDD) as the drug’s primary lead indication. HSDD is defined as a persistent or recurrent deficiency of sexual thoughts and desire that causes marked distress.
-
Testosterone operates within central neural pathways (involving dopamine and serotonin modulation in the hypothalamus) to govern spontaneous desire and sexual receptivity.
-
Unlike flibanserin (Addyi) or bremelanotide (Vyleesi), which act as neurochemical modulators often associated with nausea or hypotension, androgen replacement directly targets the underlying endocrine deficiency driving postmenopausal HSDD.
B. Energy, Motivation, and Combating “Brain Fog”
A hallmark complaint during the climacteric transition is chronic fatigue accompanied by cognitive sluggishness. Androgen receptors are widely distributed throughout the hippocampus, amygdala, and prefrontal cortex. Balanced androgen signaling supports neuroplasticity, working memory, and mental vigor.
C. Body Composition: Muscle Tone and Fat Distribution
As estrogen drops, visceral abdominal adiposity rises and muscle protein synthesis slows down. Testosterone is naturally anabolic:
-
It facilitates nitrogen retention and amino acid uptake in skeletal muscle.
-
By stimulating muscular tone and preserving lean body mass, it helps counterbalance the slowing basal metabolic rate that frequently accompanies menopause.
D. Bone Mineral Density and Fracture Prevention
While estrogen slows osteoclastic bone resorption, testosterone stimulates osteoblastic bone formation. While standard therapy addresses one half of the remodeling equation, optimal androgen tone supports overall structural bone density and mechanical strength.
3. How the Clinical Trials Are Progressing
Developing an entirely novel, regulated hormone therapy for women involves rigorous clinical, pharmacokinetic, and toxicology hurdles.
Regulatory Engagements & Preclinical Data
-
The FDA Type B Meeting: Aviva Bio participated in a formal Type B consultation with the FDA, securing written regulatory alignment on the developmental roadmap and safety benchmarks required for registration.
-
The Historic FDA Workshop: The FDA hosted a landmark public workshop titled “Testosterone Use in Menopausal Women,” highlighting an unmet clinical need while demanding clear answers on long-term breast and cardiovascular profiles. Aviva positioned AVA-291 directly against these exact concerns.
-
Cellular Proof of Concept: At major endocrinology and oncology meetings (including ENDO and AACR), data showed that eliminating the aromatase conversion step substantially reduced the risk of spurring ER-positive cell growth.
Moving Into Human Trials
Aviva Bio transitioned the molecule into First-in-Human/Phase 1 clinical studies.
-
Phase 1 Objectives: Primary Phase 1 studies evaluate bioavailability, pharmacokinetics (how d3-T is absorbed, distributed, and cleared relative to ordinary T), cutaneous absorption, and dose-proportionality in healthy adult volunteers.
-
Phase 2 Pipeline: Successful Phase 1 readouts will trigger dose-ranging Phase 2 trials specifically targeting postmenopausal women with diagnosed HSDD. These trials will establish the lowest effective therapeutic window to restore physiological levels without triggering androgenic side effects (such as hirsutism, alopecia, or acne).
-
Phase 3 Pivotal Program: Phase 3 registration studies will require multi-center cohorts evaluated over 24 to 52 weeks to prove statistically significant improvements in Satisfying Sexual Events (SSEs) and reductions in distress scores compared against a placebo.
4. Projected Timeline: When Could AVA-291 Be Approved and Released?
Because AVA-291 is a New Chemical Entity (NCE) entering Phase 1/early-stage human trials, prospective patients should recognize that commercial pharmaceutical development requires several structured steps:
┌────────────────────────────────────────────────────────┐
│ ESTIMATED DEVELOPMENT ROADMAP │
├─────────────────────┬──────────────────────────────────┤
│ Phase │ Estimated Window │
├─────────────────────┼──────────────────────────────────┤
│ Phase 1 Clinical │ Completed / Readouts │
│ Phase 2 (Dosing) │ 2027 – 2028 │
│ Phase 3 (Pivotal) │ 2028 – 2030 │
│ FDA NDA Submission │ 2030 – 2031 │
│ Commercial Launch │ 2031 – 2032 │
└─────────────────────┴──────────────────────────────────┘
-
Safety Fast-Tracking Potential: Because the safety profile of the parent compound (testosterone) is well characterized across decades of observational clinical data, if Aviva Bio shows that d3-T behaves similarly in target tissues while avoiding the breast cancer signal, regulators may consider expedited review pathways.
-
Patent Runway: Aviva Bio holds issued patents on AVA-291 covering the treatment of sexual disorders in women that extend through at least 2041 (with prospective extensions stretching to 2044), giving the company solid commercial backing to see the multi-year trial through to standard commercialization.
5. What Should Menopausal Women Do in the Meantime?
While AVA-291 works its way through clinical pipelines, women suffering from postmenopausal androgen deficiency do not have to wait in silence.
-
Get an Accurate Hormonal Workup: Women’s total testosterone is measured in nanograms per deciliter (ng/dL)—typically ranging from 15 to 70 ng/dL in reproductive years and often dipping below 10–15 ng/dL after menopause. Assess total testosterone and Sex Hormone-Binding Globulin (SHBG) via equilibrium dialysis or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), not standard immunoassays, which lack sensitivity at lower female concentrations.
-
Consult Specialist Societies: Seek out practitioners credentialed by The Menopause Society (formerly NAMS) or the International Society for the Study of Women’s Sexual Health (ISSWSH). Both clinical organizations endorse the evidence-based use of off-label transdermal testosterone titrated specifically to female physiological levels for postmenopausal HSDD.
-
Avoid Male-Dosed Formulations Without Strict Supervision: Never self-administer male-dosed testosterone gels without medical guidance. Male pumps or sachets deliver 50 to 100 mg of testosterone daily; a physiological female replacement requires approximately one-tenth of that dose (e.g., ~0.5 mg/day).
A Paradigm Shift for Women’s Health
For decades, female hormone optimization stopped abruptly at estrogen and progesterone. By fundamentally addressing the biological fear of aromatization at the molecular level, AVA-291 represents a critical next step toward an FDA-regulated, female-specific androgen therapy.
If clinical trials validate its initial preclinical safety and efficacy data, AVA-291 could redefine menopause management—giving clinicians a targeted option to restore vitality, strength, and intimacy without compromising long-term breast health.
Tags: Female testosterone doctor portland, menopause doctor testosterone, testosterone females aging, testosterone hormone optimization women portland, testosterone injection therapy, testosterone menopause, testosterone pellet therapy, Testosterone Pellets portland, testosterone women, Topical testosterone, women testosterone therapyCategories: Uncategorized